Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus

Labudovic, Danica; Toseska, Katerina N; Alabakovska, S.; Todorova, B.

doi:10.1016/s0009-9120(03)00065-1

Cited by 15 publications

(16 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They approximated that patients with diabetes have about 11% (4-17%) lower serum Lp(a) levels compared to the reference values. However, this result is not in line with most of the studies which have directly measured serum Lp(a) levels in patients with diabetes [28][29][30], including the present study. High serum Lp(a) levels are a powerful risk factor for coronary artery disease both in the general population and patients with diabetes [14,[36][37][38][39].…”

Section: Discussioncontrasting

confidence: 99%

“…There are controversial reports on the effect of diabetes on serum Lp(a) levels. In agreement with our findings, some studies have shown increased levels of serum Lp(a) in patients with diabetes [28][29][30]. Koschinsky et al [28] demonstrated higher levels of serum Lp(a) in patients with diabetes.…”

Section: Discussionsupporting

confidence: 93%

“…Koschinsky et al [28] demonstrated higher levels of serum Lp(a) in patients with diabetes. Similarly, Labudovic et al [29] showed increased serum Lp(a) levels in patients with diabetes which predicted the risk of atherosclerosis in these patients. Serum Lp(a) concentration also decreased by insulin treatment in nonobese patients with type 2 diabetes [30].…”

Section: Discussionmentioning

confidence: 84%

See 2 more Smart Citations

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Nakhjavani¹,

Morteza²,

Esteghamati³

et al. 2010

Lipids

View full text Add to dashboard Cite

Women with diabetes are faced with a higher risk of dyslipidemia and cardiovascular disorders than men with diabetes. We aimed to study the role of gender and menopausal status in serum Lp(a) levels in patients with type 2 diabetes. We quantified serum Lp(a) levels in a group of 477 patients with type 2 diabetes (men, premenopausal and postmenopausal women with diabetes), as well as in 105 controls. We stratified the patients into two groups of low Lp(a) levels (Lp(a) <35 mg/dl) and elevated Lp(a) levels (Lp(a) >35 mg/dl). Patients with diabetes had higher serum Lp(a) levels than the controls. Serum Lp(a) levels was significantly higher in women with diabetes than men with diabetes. Lp(a) levels did not differ between male and females in the control group. Premenopausal and postmenopausal women with diabetes did not differ significantly in serum Lp(a) levels. The odds ratio of having a serum Lp(a) level higher than 35 was 5.85 in premenopausal women with diabetes, 5.08 in postmenopausal women with diabetes, 2.41 in men with diabetes and 1.9 in the women in the control group compared to the men in the control group, after adjustment for age and BMI. This observational study clearly indicated that serum Lp(a) levels were significantly higher in women and men with diabetes. The increase in women was independent of menopause. The level of serum Lp(a) had no correlation with lipid parameters in men or women.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Nakhjavani¹,

Morteza²,

Esteghamati³

et al. 2010

Lipids

View full text Add to dashboard Cite

show abstract

“…In contrast, several studies reported a higher preva lence of low molecular weight isoforms in NIDDM (250)(251)(252). Findings to date underscore that larger studies using more defined populations are required to better under stand the relationship of Lp(a) concentrations and apo(a) phenotypes with diabetes mellitus.…”

Section: Kidney Diseasementioning

confidence: 93%

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

Enkhmaa

Anuurad

Berglund

2016

Journal of Lipid Research

190

134

View full text Add to dashboard Cite

“…Lipoprotein(a) blood plasma concentrations are elevated in patients with type 2 diabetes (20,21). Such elevation results in an enhanced risk of atherosclerosis (22,23).…”

Section: Introductionmentioning

confidence: 99%

The Mechanism by Which Flaxseed Oil Consumption Increases Bleeding Time in Patients with Type 2 Diabetes in Cape Breton, Nova Scotia, Canada is Independent of Lipoprotein(a) Concentration

et al. 2005

View full text Add to dashboard Cite

Platelet hyper-aggregation is a serious manifestation of type 2 diabetes and a precipitating factor in the most frequent cause of death in patients with type 2 diabetesmyocardial infarction. Consumption of flaxseed oil as a dietary supplement containing alphalinolenic acid (ALA, 18:3 n-3) through its metabolism to eicosapentaenoic acid (EPA, 20:5 n-3) and subsequent production of antiaggregatory eicosanoids may reduce such aggregation in vivo. Lipoprotein(a) (Lp (a)) may also influence platelet aggregation in vivo. Furthermore, serum Lp(a) concentrations are increased and bleeding time is decreased in patients with type 2 diabetes, presenting an enhanced risk of myocardial infarction. It was hypothesized that Lp(a) and bleeding time would be correlated due to the considerable molecular homology between apolipoprotein(a) and plasminogen, which should decrease bleeding time. Bleeding time is an excellent measure of in vivo platelet aggregability. The purpose of this study was to determine, if as the result of flaxseed oil consumption, Lp(a) influences the mechanism of any change in bleeding time. A secondary purpose was to determine if gender differences exist in the response of bleeding time to Lp(a) in flaxseed oil consumers. Subjects (n = 40) were randomized to treatment with flaxseed oil (n = 20) or a safflower oil placebo (n = 20). Each of groups contained equal numbers of males (n = 10) and females (n= 10). Some subjects dropped from the study due to reasons not related to treatment side effects. Subjects came for three visits, each three months apart. On each visit, age, gender, and BMI were recorded, bleeding time was performed, and serum Lp(a) concentrations were determined. At the completion of visit 2, subjects were randomized to 1 g of oil per 10 kg body weight each day for three months. Compared with pretreatment measurements, there was a statistically significant increase in bleeding time in the flaxseed oil group among both males and females posttreatment. In contrast, there was no change in the safflower group regardless of gender. Males had a statistically shorter bleeding time pretreatment while males and females showed no difference posttreatment with flaxseed oil consumption. Pretreatment values for Lp(a) and bleeding time showed a nonsignificant correlation among males and a statistically significant correlation among females. A statistically significant correlation also held when all males and females in the study were combined though at a lower value than in females. Significant correlations were lost and/or maintained upon administration of flaxseed oil and safflower oil, respectively. It is also concluded that serum Lp(a) concentrations remain unchanged following flaxseed oil consumption; thus, at least in part

show abstract

Apoprotein(a) phenotypes and plasma lipoprotein(a) concentration in patients with diabetes mellitus

Cited by 15 publications

References 39 publications

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Serum Lipoprotein(a) Levels are Greater in Female than Male Patients with Type‐2 Diabetes

Lipoprotein (a): impact by ethnicity and environmental and medical conditions

The Mechanism by Which Flaxseed Oil Consumption Increases Bleeding Time in Patients with Type 2 Diabetes in Cape Breton, Nova Scotia, Canada is Independent of Lipoprotein(a) Concentration

Contact Info

Product

Resources

About